RE:be carefulHey Bus... You are not telling us anything that we don't already know about a possible second phase 3. But based on the article: Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals, we look to be in good shape. Not to mention, most of us don't likely have a lot of downside on this trade at .37 On the flipside, this could become a first line treatment in the future... I like the long term prospect and risk reward on Telesta, as do others on this site. Please peddle your fear elsewhere unless you have something quantitative to share.
Link: https://clincancerres.aacrjournals.org/content/early/2013/06/10/1078-0432.CCR-13-0316.full.pdf